Isthmus Partners’s BioSpecifics Technologies Corp. BSTC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-22,310
| Closed | -$1.18M | – | 148 |
|
|
2020
Q3 | $1.18M | Buy |
22,310
+411
| +2% | +$25.4K | 0.28% | 68 |
|
|
2020
Q2 | $1.34M | Buy |
21,899
+254
| +1% | +$14.7K | 0.33% | 55 |
|
|
2020
Q1 | $1.22M | Sell |
21,645
-621
| -3% | -$35.4K | 0.38% | 52 |
|
|
2019
Q4 | $1.27M | Buy |
22,266
+150
| +0.7% | +$7.95K | 0.29% | 75 |
|
|
2019
Q3 | $1.18M | Buy |
22,116
+872
| +4% | +$50.8K | 0.28% | 76 |
|
|
2019
Q2 | $1.27M | Buy |
21,244
+19,546
| +1,151% | +$1.23M | 0.3% | 62 |
|
|
2019
Q1 | $648K | Sell |
1,698
-19,379
| -92% | -$1.28M | 0.16% | 109 |
|
|
2018
Q4 | $1.28M | Buy |
21,077
+1,552
| +8% | +$92.7K | 0.38% | 53 |
|
|
2018
Q3 | $1.14M | Buy |
19,525
+204
| +1% | +$10.4K | 0.29% | 61 |
|
|
2018
Q2 | $867K | Buy |
19,321
+738
| +4% | +$31.7K | 0.23% | 91 |
|
|
2018
Q1 | $824K | Buy |
18,583
+1,177
| +7% | +$49.4K | 0.22% | 87 |
|
|
2017
Q4 | $754K | Buy |
17,406
+653
| +4% | +$29.4K | 0.21% | 88 |
|
|
2017
Q3 | $779K | Buy |
16,753
+248
| +2% | +$11.9K | 0.22% | 87 |
|
|
2017
Q2 | $817K | Sell |
16,505
-384
| -2% | -$20.1K | 0.24% | 78 |
|
|
2017
Q1 | $926K | Sell |
16,889
-151
| -0.9% | -$7.99K | 0.27% | 58 |
|
|
2016
Q4 | $949K | Sell |
17,040
-701
| -4% | -$33.7K | 0.29% | 58 |
|
|
2016
Q3 | $782K | Buy |
17,741
+346
| +2% | +$13.9K | 0.25% | 64 |
|
|
2016
Q2 | $695K | Buy |
+17,395
| New | +$637K | 0.23% | 70 |
|
Other funds holding BSTC
Isthmus Partners's BSTC Position: Q4 2020 in Review
Isthmus Partners sold out of BioSpecifics Technologies Corp. (BSTC) in Q4 2020, closing a stake of 22,310 shares — an estimated $1.18M sold.
Isthmus Partners first reported a position in BSTC in Q2 2016 and held it in 18 quarters. The position peaked at $1.34M in Q2 2020. 1 fund tracked by Wall St. Rank holds BSTC as of Q4 2020.
- Isthmus Partners reported no remaining BioSpecifics Technologies Corp. position as of Q4 2020 after selling out during the quarter.
- Isthmus Partners sold 22,310 BioSpecifics Technologies Corp. shares in Q4 2020, an estimated $1.18M.
- Isthmus Partners first reported a position in BioSpecifics Technologies Corp. in Q2 2016 and held it in 18 quarters.
- Isthmus Partners's BioSpecifics Technologies Corp. position peaked at $1.34M in Q2 2020.
- 1 fund tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q4 2020.
Based on Isthmus Partners's 13F filing for Q4 2020, filed 16 Feb 2021.